NEWS
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics (NASDAQ: ALRN) is presenting data from its Phase 1b clinical trial of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis. The trial's Cohort 1, evaluating low-dose LTI-03 (2.5 mg BID), showed positive trends in seven out of eight biomarkers, with three showing statistically significant improvements in collagen synthesis, inflammation, and fibrogenesis.
The company has also completed enrollment for Cohort 2, testing high-dose LTI-03 (5 mg BID), with topline data expected soon. Pre-clinical data using precision cut lung slices (PCLS) further supports LTI-03's potential effectiveness in IPF treatment. The ongoing Phase 1b trial aims to evaluate the safety and tolerability of LTI-03 in IPF patients over 14 days of treatment.
The company has also completed enrollment for Cohort 2, testing high-dose LTI-03 (5 mg BID), with topline data expected soon. Pre-clinical data using precision cut lung slices (PCLS) further supports LTI-03's potential effectiveness in IPF treatment. The ongoing Phase 1b trial aims to evaluate the safety and tolerability of LTI-03 in IPF patients over 14 days of treatment.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
Spread kindness and love. Life is short. Don’t let greed eat you.
2808フォロワー
108フォロー中
30K訪問者
フォロー